Could Patient Stratification Help Lilly Finally Unlock An Alzheimer’s Breakthrough?

Tau Status Stratification Unique To Lilly Trial

Lilly believes its approach can help identify the Alzheimer’s patients who would benefit most from a beta amyloid clearing therapy – but skepticism about the mechanism itself remains widespread.

Lilly's TRAILBLAZER 2 will be the last of the three competitor trials to read out, in mid-2023. • Source: Michael Vi / Shutterstock.com

As the readouts from three late-stage Alzheimer’s disease drug candidates draw nearer, hopes are again rising that a breakthrough may finally be possible – but given the string of failures over the last 20 years, many are skeptical about the chances of success for the beta-amyloid targeting antibody therapies.

Eli Lilly believes its patient-stratification approach could give it the edge, but its readout looks set to be the last of the trio; Biogen and Eisai’s lecanemab...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

30 May 2025

• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

29 May 2025

• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

29 May 2025

• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

29 May 2025

• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback